Adjunctive alpha-lipoic acid therapy considerably reduced inflammation and improved cardiac function in diabetic patients with ischemic cardiomyopathy (P<0.05).
RCT (n=67)
Double-blind
randomized
No
Does alpha-lipoic acid reduce inflammation and improve cardiac function in diabetic patients with ischemic cardiomyopathy?
Alpha-lipoic acid added to standard therapy may reduce inflammation and improve cardiac function in diabetic patients with ischemic cardiomyopathy.
p-value: p=<0.05
BACKGROUND: Ischemic cardiomyopathy (ICM) is caused by oxidative stress, inflammation, and apoptosis. Alpha-lipoic acid (ALA) has antioxidant and anti-inflammatory effects. However, its effects on left ventricular dysfunction and myocardial fibrosis remain unclear. OBJECTIVE: This study aims to investigate the effects of ALA on cardiac inflammation, fibrosis, and myocardial function as an adjuvant therapy for ICM. METHODS: This double-blind, randomized, placebo-controlled, single-center trial enrolled 67 diabetic patients with ICM, who were randomized to receive either ALA 600 mg once daily or placebo for three months, in addition to ICM medications. Both groups were evaluated for tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP), tissue growth factor-β1 (TGF-β1), matrix metalloproteinase-2 (MMP-2), and some echocardiographic indices before and after treatment. RESULTS: < 0.05), respectively. CONCLUSION: Adjunctive ALA therapy considerably reduced inflammation and improved cardiac function in patients with ICM. Additionally, our findings suggest that ALA may influence profibrotic signaling.
Shama et al. (Tue,) conducted a rct in Ischemic cardiomyopathy in type 2 diabetic patients (n=67). Alpha-lipoic acid (ALA) vs. Placebo was evaluated on Tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP), tissue growth factor-β1 (TGF-β1), matrix metalloproteinase-2 (MMP-2), and echocardiographic indices (p=<0.05). Adjunctive alpha-lipoic acid therapy considerably reduced inflammation and improved cardiac function in diabetic patients with ischemic cardiomyopathy (P<0.05).